INTRODUCTION
Approximately 15% to 20% of newly diagnosed invasive breast cancers have intrachromosomal human epidermal growth factor receptor 2 (HER2) gene amplification and protein overexpression. [1] [2] [3] The accurate evaluation of HER2 status determines eligibility for HER2-targeted therapies. The humanized monoclonal antibody trastuzumab is highly effective and has an excellent safety profile. 4 Recent studies have indicated that newer anti-HER2 agents (eg, pertuzumab and lapatinib) are also effective for many patients. 5 Guidelines for the interpretation and reporting of HER2 test results were published in 2007 by the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) 6 and were updated in 2013. 7 In 2007 and 2013, an ASCO/CAP expert panel did not mandate the selection of immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) for first-line HER2 testing. Most laboratories use IHC for primary HER2 testing, whereas FISH is used as the initial test method in many large academic and reference laboratories and is the reflex testing method for tumor specimens with equivocal (21) IHC results.
The most commonly used FISH assays are the US Food and Drug Administration (FDA)-approved dualprobe assays with fluorochrome-labeled probes for HER2 on the long arm of chromosome 17 and a separate probe for chromosome 17 that hybridizes to a site near the centromere (the centromere enumeration probe for chromosome 17 [CEP17]). After counting HER2 and chromosome 17 signals in a subset of tumor cells, an HER2:CEP17 ratio is generated, with ratios 2.0 classified as amplified. 7 The chromosome 17 probes are used to control for the possibility that an apparent alteration in HER2 copy number could be related to the truncation of nuclei in tissue sections prepared for FISH, duplication of the HER2 gene during mitosis, and aneusomy (especially polysomy) for chromosome 17. However, studies using comparative genomic hybridization and multiplex ligation-dependent probe amplification have demonstrated that whole chromosome polysomy for chromosome 17 is uncommon in breast tumors. 8, 9 Copy number alteration (CNA) in DNA at the control probe hybridization sites may explain the increased number of chromosome 17 signals in many tumors. 10 There are conflicting data on HER2 protein overexpression in these tumors, 10 and "polysomy," as indicated by an increased CEP17 copy number, does not appear to be correlated with increased HER2 messenger RNA expression. 11 The current ASCO/CAP guidelines recommend consideration of testing with an alternative chromosome 17 probe in patients with equivocal FISH results. 7 Some studies suggest that alternative chromosome probes may "correct" the estimation of chromosome 17 copy numbers but the sites to which the alternative probes hybridize are also sometimes subject to CNA. 12, 13 The objective of the current study was to assess the impact of an alternative chromosome 17 probe (D17S122), which has relatively stable copy numbers in breast carcinoma, 14 on the assessment of HER2 gene amplification by FISH. We also analyzed the impact of the 2013 ASCO/CAP guidelines on the reclassification of HER2 gene amplification status.
MATERIALS AND METHODS
This study was approved by the Cleveland Clinic Institutional Review Board. The study population was selected from 3048 patients with primary and metastatic breast cancer who underwent dual-probe FISH for HER2 gene status at the Cleveland Clinic from January 2013 to June 2015. A subset of 310 tumor specimens (from 287 patients) with CEP17 CNA underwent reflex testing in a second FISH assay using an alternative chromosome 17 probe. CEP17 CNA was defined as an average signal count between <1.5 and 2.6.
12,13
The distribution of specimens assigned to each HER2 category by D17S122 and the 2007 and 2013 guidelines was compared using the chi-square test. The Fisher exact test was used to analyze proportions. P values < .05 were considered significant.
The primary method for determining HER2 status of breast carcinomas during the study period was FISH using the PathVysion HER2 DNA probe kit, (Abbott Molecular, Inc., Des Plaines, Ill). The laboratory protocols for HER2 FISH have been published elsewhere. 15 Briefly, tumors were tested with a dual-probe assay that included an HER2 gene probe labeled in Spectrum Orange, with CEP17 labeled in Spectrum Green. Hematoxylin and eosin-stained, 4-lm-thick sections were evaluated to confirm invasive carcinoma; and consecutively cut, unstained sections were analyzed by HER2:CEP17 FISH according to the manufacturer's recommendations. For the initial HER2:CEP17 FISH analysis, 2 areas of 20 cells each were analyzed in a region designated by a breast pathologist as invasive carcinoma. If the results of the initial analysis were equivocal, then a second observer counted an additional 20 cells in the same region of invasive carcinoma, and the final results were reported based on the signal counts and the ratio obtained for 60 cells.
To develop an alternative chromosome 17 probe, a highly conserved region on the short arm of chromosome 17 ("D17S122") was identified using a molecular inversion probe array approach 16 and the OncoScan formalinfixed, paraffin-embedded assay kit (Affymetrix, Santa Clara, Calif), as previously described.
14 Analysis of the molecular inversion probe data was performed using Nexus Copy Number software by BioDiscovery (Hawthorne, Calif). The HER2:D17S122 probe set was synthesized by Empire Genomics (Buffalo, NY). Consecutively cut, 4-lm-thick, unstained sections were analyzed by HER2:D17S122 FISH as previously described. 17 The D17S122 and HER2 probes were labeled with Spectrum Green and Spectrum Orange, respectively. Signal counting was performed using the same protocol as for the initial HER2:CEP17 FISH. More detailed information on the location of probes used in HER2:CEP17 and HER2: D17S122 FISH are provided in the Supporting Materials and Methods (see online supporting information). Pathology and FISH reports were retrieved from the anatomic pathology information system CoPathPlus (Cerner Corporation, Kansas City, Mo) and were reviewed by a dedicated breast pathologist. Treatment data and patient demographics were obtained from the electronic medical record (Epic Systems Corporation, Verona, Wis). The study was approved by the Institutional Review Board of the Cleveland Clinic with a waiver of consent.
RESULTS
Of the 310 specimens with CEP17 CNA that were tested with HER2:CEP17 FISH and underwent reflex testing with HER2:D17S122 FISH, 215 (69.4%) had an average of 2.6 CEP17 signals. Lower chromosome 17 copy numbers (ie, <2.6) were obtained in 129 specimens (60%) when D17S122 was used. Of the 90 specimens (29%) that had an average of <1.5 CEP17 signals, 85 (94.4%) had a mean of 1.5 chromosome 17 copy numbers with D17S122. Only 16 of 90 specimens (17.8%) with an average of <1.5 CEP17 signals were amplified under the 2013 ASCO/CAP guidelines, and 10 of those had average HER2 copy numbers <4.0. A schematic representation of the positions of the CEP17, D17S122, and HER2 probes on chromosome 17 is provided in Figure 1 .
Distribution of Breast Cancer Specimens by FISH Assays
The results of HER2 FISH using CEP17 and D17S122 with the 2007 and 2013 ASCO/CAP guidelines are provided in Table 1 . By using CEP17 and following the 2007 ASCO/CAP guidelines, there were 49 (15.8%) amplified, 25 (8.1%) equivocal, and 236 (76.1%) nonamplified specimens. With CEP17 and the 2013 ASCO/CAP guidelines, there were 67 (21.6%) amplified, 73 (23.6%) equivocal, and 170 (54.8%) nonamplified specimens (P < .001). The proportion of specimens classified as equivocal was significantly higher using the 2013 guidelines (P < .001). The fraction of specimens classified as amplified was higher under the 2013 guidelines, but the difference did not reach statistical significance (P 5 .08). The variation in HER2 and chromosome 17 copy number estimates between the initial HER2:CEP17 FISH assay and the reflex HER2:D17S122 FISH assay and the impact on reclassification under the 2013 guidelines is detailed in Supporting Table 1 (see online supporting information). Reflex HER2:D17S122 FISH changed the interpretation in 82 of 310 (26.5%) and 87 of 310 (28.1%) specimens using the 2007 and 2013 guidelines, respectively. According to the 2007 guidelines, 41 of 310 (13.2%) specimens from 39 patients were reclassified from nonamplified to amplified: 28 (68.3%) specimens had mean HER2 copy numbers between 4.0 and <6.0, 9 (22%) had mean HER2 copy numbers between <4.0, and 4 (9.7%), had 6.0 HER2 copy numbers on the initial HER2:CEP17 FISH. According to the 2013 guidelines, 39 of 310 (12.6%) specimens from 38 patients were reclassified from equivocal to amplified, all of which had mean HER2 copy numbers between 4.0 and <6.0 and mean CEP17 copy numbers 2.6 on the initial HER2:-CEP17 FISH. Representative images of a case that was converted from equivocal to amplified with the D17S122 probe are shown in Figure 2 .
Reflex HER2:D17S122 FISH also changed the distribution of specimens across the 5 FISH groups reported by Press et al 18 Table 2 . There were 39 of 73 (53.4%) equivocal results (ratio, <2.0 [mean HER2 copy numbers, between 4.0 and <6.0]) that were reclassified as amplified with HER2:D17S122 FISH, including 33 with a ratio 2.0 and a mean of 4.0 HER2 copy numbers, 5 with a ratio 2.0 and a mean of <4.0 HER2 copy numbers, and 1 with a ratio <2.0 and a mean of 6.0 HER2 copy numbers. On the initial HER2:CEP17 FISH assay, 44 of 310 (14.2%) specimens had FISH-positive results with a ratio 2.0 and a mean of 4.0 HER2 copy numbers. On reflex HER2:D17S122 FISH testing, there were 93 of 310 (30%) FISH-positive results with a ratio 2.0 and a mean of 4.0 HER2 copy numbers (P < .001). (21) human epidermal growth factor receptor-2 (HER2) immunohistochemistry (original magnification 3400); (C) standard fluorescence in situ hybridization (FISH) for HER2 (Spectrum Orange) and the chromosome 17 centromere enumerator probe (CEP17) (Spectrum Green) with an HER2:CEP17 ratio of 1.2; and (D) FISH for HER2 (Spectrum Orange) and the D17S122 probe (Spectrum Green) with an HER2:D17S122 ratio of 2.1.
Clinicopathologic Characteristics
Under the current ASCO/CAP guidelines, the largest subset of patients that had a clinically significant reclassification based on testing with the D17S122 probe is the group of 38 patients whose HER2 status changed from equivocal to amplified. The HER2 FISH and IHC data, hormone receptor status, and their treatment information are summarized in Table 3 . This group consisted of 36 women and 2 men with a median age of 62 years (age range, 35-87 years). The tumor size was unknown in 6 patients (15.8%), and 3 specimens (7.9%) were biopsies of metastatic lesions. Of the remaining 29 specimens, 17 (58.6%) measured <2.0 cm (pathologic T1 tumor [pT1]), 11 (37.9%) measured between >2.0 and <5.0 cm (pT2), and 1 (3.5%) measured >5.0 cm (pT3). All but 1 of these tumors had an intermediate or high combined histologic grade (96.5%). Lymph node status was known for 30 patients (78.9%): 21 (70.1%) had no positive lymph nodes (pN0), 7 (23.3%) had 1 to 3 positive lymph nodes (pN1), 1 (3.3%) had 4 to 9 positive lymph nodes (pN2), and 1 (3.3%) had >10 positive lymph nodes (pN3). All specimens had an initial HER2:CEP17 ratio <2.0, including 2 with a ratio of 1.8 and 1 with a ratio of 1.9. Of the 13 specimens (34.2%) with available HER2 IHC results, 10 (76.9%) were scored 21, and the scores for the remaining 3 specimens were 0, 11, and 31. The specimen with a 31 
Patient Treatment
Treatment data were available for 31 patients (81.6%): 24 (77.4%) received HER2-targeted therapy (in addition to chemotherapy), and 26 (83.9%) received endocrine therapy. With a median of 31 months of follow-up (range, 3-46 months), none of these patients, including those who did not receive HER2-targeted therapy, experienced disease recurrence or progression. There was considerable overlap in the groups of patients who had results reclassified from equivocal to amplified with D17S122 under the 2013 guidelines and negative to amplified under the 2007 guidelines. Of the 38 patients who were reclassified from equivocal to amplified with D17S122 according to following the 2013 guidelines, 27 (71.1%) were reclassified from negative to amplified using the 2007 guidelines. Of the remaining 11 patients who were reclassified from negative to amplified according to the 2007 guidelines, 7 of 11 (63.6%) were known to have received HER2-targeted therapy. Therefore, of the total of 49 patients who were reclassified either from Abbreviations: Average HER2, average human epidermal growth factor receptor 2 (HER2) copy numbers; CEP17, centromere enumerator probe for chromosome 17; D17S122, alternative chromosome 17 probe; FISH, fluorescence in situ hybridization.
equivocal to amplified using 2013 guidelines or from negative to amplified following 2007 guidelines, 31 of 49 (63.3%) were known to have received HER2-targeted therapy. Of these 49 patients, 2 (4.1%) presented with metastatic disease and died soon after diagnosis. None of the remaining patients in this group have had a recurrence or progression of disease during the follow-up period.
DISCUSSION
The most commonly used FISH test for the assessment of HER2 gene amplification in breast cancer is a dual-probe assay with probes for the HER2 gene and a reference locus on chromosome 17 (CEP17). The CEP17 probe hybridizes to a site near the centromere of chromosome 17. The use of this control probe was intended to correct for potential errors in the estimation of HER2 gene copy numbers that could be caused by an entire nucleus not being in the plane of section (ie, truncation), duplication of chromosomes during mitosis, or aneusomy of chromosome 17. Under the 2007 ASCO/CAP guidelines, results were primarily reported as the HER2:CEP17 ratio. 6 However, as many laboratories gained more experience with the dual-probe FISH assay, it became apparent that CNA in the a-satellite DNA at the centromeric hybridization site for CEP17 could affect the assessment of HER2 status by skewing the ratio. [19] [20] [21] Coamplification of CEP17 and HER2 has also been reported, 22, 23 and the alternative chromosome 17 probe for the D17S122 locus resolves HER2 gene amplification status in many of these tumors. 17 In current practice, this is a relatively well recognized (albeit uncommon) issue, and tumors with mean HER2 copy numbers >6.0 should be reported as amplified under the 2013 guidelines, irrespective of the HER2:CEP17 ratio. Furthermore, tumors with coamplification of CEP17 and HER2 are almost always strongly positive (31) on IHC. 22 Before publication of the 2013 ASCO/CAP guidelines, 7 the ratio of HER2 signals to chromosome 17 signals was the only FISH result that was used to determine HER2 gene amplification status. The most significant changes in the 2013 guidelines were the elimination of an equivocal range for the ratio and the requirement to report all tumors with a mean HER2 copy number between 4.0 and <6.0 and ratios <2.0 as equivocal. The emphasis on the mean HER2 signal number, irrespective of the mean CEP17 signal number, represents an attempt to address issues related to CEP17 CNA. The updated guidelines also included a recommendation to consider additional testing with an alternative probe for chromosome 17 in specimens with equivocal FISH results. In practice, the routine use of alternative chromosome 17 probes in equivocal specimens appears to be limited to a few large academic or reference laboratories.
Several studies have examined the impact of the 2013 ASCO/CAP guidelines on the assessment of HER2 gene amplification status in breast cancer. In most series, the application of the current guidelines increased the number of equivocal and/or amplified specimens, [24] [25] [26] [27] [28] and this appeared to be especially true among those that had equivocal (21) IHC results. [29] [30] [31] [32] [33] [34] In a series enriched for CEP17 CNA, we also observed an increase in specimens classified as equivocal or amplified under the 2013 guidelines. Others studies have demonstrated that tumors with CEP17 CNA are more likely to be impacted by the 2013 ASCO/ CAP guidelines and classified as equivocal. 29, 35 In some specimens, the change in HER2 copy number, with or without a change in chromosome 17 copy number, as assessed with D17S122, was sufficient to reclassify a specimen from equivocal to amplified (Table 3  and Supporting Table 1 ; see online supporting information). The HER2 probe used with D17S122 differs from the HER2 probe used with CEP17 by only a few base pairs, and this difference seems unlikely to alter the number or intensity of HER2 signals. Factors contributing to the variability assessment of HER2 copy number could include: 1) the relatively small sample size of 40 to 60 nuclei counted in each FISH assay, and/or 2) counting nuclei that may have had a different mean HER2 copy number per nucleus. The variability that may be related to a limited sample size is inherent to the manual counting of HER2 FISH signals in 40 to 60 cells. We attempted to mitigate the potential variability related to the second of these 2 factors by using unstained slides (serial sections) that were cut at the same time as the slides produced for the initial HER2:CEP17 FISH analysis. In addition, all HER2 signal counts were conducted in the same area of invasive carcinoma that was originally identified by a breast pathologist for HER2:CEP17 FISH. Any amount of variability in HER2 signal assessment is likely to have a greater impact on the classification of this highly selected group of specimens with CEP17 CNA and equivocal results from HER2:CEP17 FISH.
Two of the larger studies of alternative chromosome 17 probes were reported by Tse et al 12 and Jang et al. 13 Those studies examined the potential utility of probes for the Smith-Magenis syndrome (SMS), retinoic acid receptor-a (RARA), and tumor protein p53 (TP53) genes in determining chromosome 17 copy number in specimens with a mean of 2.6 CEP17 signals per nucleus (Fig. 2) . Both studies reported an increase in specimens classified as equivocal or amplified based on results from using the alternative chromosome 17 probes. Those authors also noted copy number variations in the loci for SMS, RARA, and TP53, potentially limiting their utility in correcting for CEP17 CNA. In contrast, the D17S122 locus at 17p11.2-12 appears to have a relatively stable copy number in breast cancer, 14, 36 and it has been demonstrated that probes for this region of chromosome 17 can resolve HER2 status in tumors with CEP17 CNA, 36, 37 including tumors that were initially classified as equivocal under the 2013 guidelines. 24 In a recent series from the Mayo Clinic 24 that was highly enriched for patients who had equivocal (21) IHC results, use of a D17S122 probe and the 2013 guidelines resulted in reclassification of approximately 52% of equivocal specimens to amplified. All of the specimens in our study that were reclassified from equivocal to amplified in that study had a mean CEP17 copy number of 2.6, and only 2 had a mean D17S122 copy number <1.5, suggesting that the reclassification of these tumors was not related to heterozygous segmental deletions of the p-arm of chromosome 17 (Table 3) .
In our study, we selected 310 with mean CEP17 copy numbers of 2.6 or <1.5 for additional testing with a single alternative chromosome 17 probe (D17S122).
14 Among the tumors with <1.5 CEP17 signals per nucleus, the results from D17S122 were very similar, suggesting that these tumors may contain a population of cells with true monosomy for chromosome 17. These results also suggest that D17S122 has limited utility in tumors with <1.5 CEP17 signals per cell. In tumors with 2.6 CEP17 signals, the use of D17S122 resulted in the reclassification of a significant number of patients. When FISH was interpreted according to the 2007 guidelines, 26.5% of tumors were reclassified using D17S122, one-half of which were converted from negative to amplified. Under the 2013 ASCO/CAP guidelines, 28.1% of tumors were reclassified using D17S122, nearly one-half of which were converted from equivocal to amplified. These results are very similar to those obtained by Shah et al 24 at the Mayo Clinic using a similar alternative chromosome 17 probe.
The majority of patients in this series who were reclassified from equivocal to amplified under the 2013 guidelines had pathologic stage I, intermediate to high histologic grade, hormone receptor-positive, lymph nodenegative disease and received treatment with endocrine therapy, HER2-targeted therapy, and chemotherapy. The clinicopathologic features of these tumors are not those typically expected for HER2-amplified tumors, but they are similar to what has been reported for the "new equivocal" tumors defined by the 2013 guidelines. 25, 31, 34, 38 All of these tumors had an HER2:CEP17 ratio <2.0, a mean HER2 copy number between 4.0 and <6.0, and a mean CEP17 copy number 2.6. These tumors also appeared to be enriched for equivocal (21) IHC results, similar to what has been reported by others for the equivocal category in the 2013 guidelines. 24, 25, 27, 28 However, a larger study of patients who were screened for enrollment in 3 BCIRG clinical trials demonstrated a significant association with HER2 IHC scores of 0 or 11 in this group. 18 The equivocal category, as defined in the 2013 ASCO/ CAP guideline, may contain the "HER2-low" patients, whose potential benefit from trastuzumab provided the basis for the National Surgical Adjuvant Breast and Bowel Project B47 trial (Trastuzumab for Women With HER2-Low Breast Cancer; available at: http://www.nsabp.pitt. edu/B-47.asp, accessed December 18, 2016). However, Long et al 26 noted that patients who had any HER2 result indicating a mean HER2 copy number 4.0 were likely to have been excluded from that trial. Others have suggested that this subset of tumors may correspond to the luminal B intrinsic molecular subtype, 31 and this remains an area for future investigation.
The use of an alternative chromosome 17 probe in the subset of patients who had HER2:CEP17 ratios <2.0 and a mean HER2 copy number between 4.0 and <6.0 leads to more patients becoming eligible for HER2-targeted therapy. However, the benefit of HER2-targeted therapy is not well established for this patient population. Press et al recently examined the relation between the HER2:CEP17 ratio and mean HER2 copy numbers with disease-free and overall survival in 10,468 patients who were screened for enrollment in BCIRG-005, BCIRG-006, and BCIRG-007. 18 The subset of patients who had HER2:CEP17 ratios <2.0 and mean HER2 copy numbers between 4.0 and <6.0 (corresponding to group 4 in the authors' classification scheme) comprised 4.1% of the study population. These patients were among those enrolled in BCIRG-005 who received chemotherapy only. 39 There was no significant difference in disease-free or overall survival when the patients in group 4 were compared with patients who had HER2:CEP17 ratios <2.0 and a mean of <4.0 HER2 copy numbers. 18 On the basis of the outcomes data and the absence of HER2 protein overexpression in this subset of patients, Press et al concluded that tumors with an HER2:CEP17 ratio <2.0 and mean HER2 copy numbers between 4.0 and <6.0 should be classified as not amplified.
In summary, in this series of breast carcinomas that were selected for CEP17 CNA, reflex testing with an additional chromosome 17 probe resulted in reclassification of greater than 25% of specimens. For specimens that were equivocal on initial HER2:CEP17 FISH according to the 2013 ASCO/CAP guidelines, nearly one-half were reclassified as amplified. The majority of these patients received HER2-targeted therapy. At our institution, D17S122 testing is currently performed on a case-by-case basis in consultation with the treating medical oncologist. Clinical trials using an alternative chromosome 17 probe in patients with CEP17 CNA to determine eligibility for HER2-targeted therapy are needed.
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